Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Dexamethasone + Elotuzumab + Iberdomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dexamethasone | Adexone | Desametasone | ||
Elotuzumab | Empliciti | BMS-901608 | Empliciti (elotuzumab) is a humanized monoclonal antibody against human CS1, which induces antibody-dependent cellular cytotoxicity in CS1-positive cells (PMID: 26005365). Empliciti (elotuzumab) is approved in combination with Revlimid (lenalidomide) and dexamethasone for use in patients with multiple myeloma (FDA.gov). | |
Iberdomide | CC220|CC-220|CC 220 | Iberdomide (CC-220) binds to the ubiquitin E3 ligase complex member Cereblon (CRBN), which may lead to increased ubiquitination and degradation of transcription factors, resulting in decreased B-cell proliferation (PMID: 29945920, PMID: 28848067, PMID: 31719682). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06518551 | Phase Ib/II | Dexamethasone + Elotuzumab + Iberdomide | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM | Not yet recruiting | USA | 0 |
NCT05560399 | Phase I | Dexamethasone + Elotuzumab + Iberdomide | A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (CC-220) | Enrolling by invitation | USA | 0 |